AKT1 and urinary bladder carcinoma: Chen et al. (2021) demonstrated that SC66 led to apoptosis and inhibits proliferation in bladder cancer cells by targeting the AKT/β-catenin pathway, indicating β-catenin's contribution to cell survival and chemoresistance (15).